Know Cancer

forgot password

ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial

18 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial

The impact of genetic factors on the natural history of prostate cancer (PC) is shown
schematically at two levels:

1. first, at the constitutional level with germline alterations. Family history is found
in 20% of PC patients. Different clinical entities associated with different modes of
inheritance, susceptibility mutations or polymorphisms, define different evolutionary
patterns. Also, studies suggested that some genetic polymorphisms alter the response to
some treatments (such as recurrence after prostatectomy or radiotherapy) or adverse
effects of those above (such as toxicity of radiation therapy).

2. secondly, PC is characterized by the accumulation of genetic alterations (somatic
alterations or acquired mutations). These changes contribute in varying degrees to the
aggressiveness of the disease (such as early metastatic potential) and treatment
failure (such as resistance to radiation or hormone resistance).

The purpose of this study is to establish a register, with a follow up of cohort type and a
collection of biological samples:

- For men with known prostate cancer.

- For men with no prostate cancer after a screening procedure for this disease, so that
their biological samples can be compared to those of men with prostate cancer.

The registry data and collected biological samples are used to identify genetic and
molecular factors involved in susceptibility, genesis and evolution of prostate cancers.

Inclusion Criteria:

- patient with a histological confirmed prostate cancer

- member of a hereditary prostate cancer family

- healthy control men without prostate cancer

Exclusion Criteria:

- Absence of signed informed consent

- refusal to participate in the study

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Olivier Cussenot, MD, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Assistance Publique - Hôpitaux de Paris


France: Direction Générale de la Santé

Study ID:




Start Date:

October 1996

Completion Date:

December 2016

Related Keywords:

  • Prostate Cancer
  • prostate
  • cancer
  • genetic
  • epidemiology
  • susceptibility
  • Prostatic Neoplasms